Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and eleven have given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $41.00.
Several brokerages have recently issued reports on VRDN. Wall Street Zen raised shares of Viridian Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 7th. Needham & Company LLC boosted their price target on Viridian Therapeutics from $34.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. HC Wainwright upped their price target on Viridian Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Truist Financial raised their price objective on Viridian Therapeutics from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Finally, Royal Bank Of Canada boosted their target price on Viridian Therapeutics from $38.00 to $41.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th.
Get Our Latest Stock Analysis on Viridian Therapeutics
Viridian Therapeutics Trading Up 0.2%
Shares of Viridian Therapeutics stock opened at $30.12 on Thursday. Viridian Therapeutics has a fifty-two week low of $13.18 and a fifty-two week high of $34.29. The business’s fifty day moving average is $23.17 and its two-hundred day moving average is $21.70. The company has a quick ratio of 14.46, a current ratio of 14.46 and a debt-to-equity ratio of 0.50. The firm has a market cap of $3.42 billion, a PE ratio of -7.84 and a beta of 1.07.
Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.21. Viridian Therapeutics had a negative return on equity of 79.67% and a negative net margin of 1,620.79%. The business had revenue of $25.75 million during the quarter, compared to the consensus estimate of $4.72 million. Analysts anticipate that Viridian Therapeutics will post -3.64 earnings per share for the current year.
Institutional Investors Weigh In On Viridian Therapeutics
Several institutional investors have recently bought and sold shares of VRDN. KBC Group NV purchased a new stake in Viridian Therapeutics during the 1st quarter worth $34,000. Integrated Wealth Concepts LLC purchased a new position in Viridian Therapeutics in the 2nd quarter valued at about $33,000. State of Wyoming acquired a new stake in shares of Viridian Therapeutics during the second quarter valued at about $43,000. Fulcrum Asset Management LLP acquired a new stake in Viridian Therapeutics during the 3rd quarter valued at approximately $97,000. Finally, AlphaCentric Advisors LLC purchased a new stake in Viridian Therapeutics during the 3rd quarter worth approximately $216,000.
About Viridian Therapeutics
Viridian Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a primary focus on thyroid eye disease (TED), an autoimmune condition that can cause inflammation and changes around the eyes. The company’s pipeline includes veligrotug, an investigational antibody that targets the insulin-like growth factor 1 receptor, a pathway involved in TED. Viridian is also developing additional antibody-based candidates intended to offer treatment options, including formulations designed for under-the-skin administration.
Featured Stories
- Five stocks we like better than Viridian Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
